3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
155
Lymphoma
20
Recurrence
17
Neoplasms
12
Hematologic Neoplasms
11
Neoplasms, Plasma Cell
9
Lymphoma, Non-Hodgkin
9
Immunoglobulin Light-chain Amyloidosis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Lymphoma, Mantle-Cell
5
Leukemia, Myeloid, Acute
5
Hodgkin Disease
5
Smoldering Multiple Myeloma
4
Prostatic Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Plasma Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia
4
Breast Neoplasms
4
Ovarian Neoplasms
3
Melanoma
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Cytokine Release Syndrome
3
Waldenstrom Macroglobulinemia
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
pomalidomide
1
daratumumab
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmacytoma
×
Plasma cell
×
30 days
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts